Semaglutide is an FDA approved treatment for chronic weight management in adults who are obese (BMI 30) and overweight adults (BMI 27 who also have at least one weight-related comorbid condition (ie
Diabetes 61 , 888896 (2012)
The primary causes of NAFLD are closely linked to metabolic syndrome and include obesity, type 2 diabetes mellitus, insulin resistance, dyslipidaemia (particularly elevated triglycerides and low HDL cholesterol), and hypertension
Documentation should include the medication name, dosage, route, site, provider order, diagnosis, medical necessity, and administration details
Certain medications might also cause this change
Researchers are exploring its ability to help people lose weight effectively while also addressing related health issues like type 2 diabetes